DSM-Firmenich Overview
- Year Founded
-
1902
- Status
-
Public
- Employees
-
30,000
- Stock Symbol
-
DSFIR
- Investments
-
85
- Share Price
-
$103.18
- (As of Wednesday Closing)
DSM-Firmenich General Information
Description
DSM-Firmenich is a global science-based company formed in 2023 through the merger of DSM, a Dutch nutrition, health, and sustainable living player, and Switzerland-based Firmenich, the third-largest player in the flavor and fragrance market. The company serves a wide range of end-consumer markets providing nutrition solutions ranging from animal feed to medical and early-life nutrition, fragrances for personal-, home-, and laundry-care brands, prestige perfumes, and other ingredients for food and beverage, home, and personal care. DSM-Firmenich has nearly 30,000 employees, with more than 2,000 scientists and engineers spread across 15 research and development facilities.
Contact Information
Website
www.dsm-firmenich.comCorporate Office
- Wurmisweg 576
- 4303 Kaiseraugst
- Switzerland
Corporate Office
- Wurmisweg 576
- 4303 Kaiseraugst
- Switzerland
DSM-Firmenich Stock Performance
As of 22-Jan-2025, DSM-Firmenich’s stock price is $103.18. Its current market cap is $27.4B.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $103.18 | $103.03 | $95.90 - $139.03 | $27.4B | 426K |
DSM-Firmenich Financials Summary
As of 30-Jun-2024, DSM-Firmenich has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 32,682,737 | 29,266,867 | ||
| Revenue | 11,499,215 | 8,821,272 | 13,530,225 | |
| EBITDA | 439,323 | 1,377,338 | ||
| Net Income | 2,312,395 | 1,787,385 | 1,030,964 | |
| Total Assets | 35,169,146 | 37,882,054 | 18,662,935 | |
| Total Debt | 4,911,461 | 5,339,081 | 3,285,826 | 0 |
DSM-Firmenich Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
DSM-Firmenich Comparisons
Industry
Financing
Details
DSM-Firmenich Competitors (18)
One of DSM-Firmenich’s 18 competitors is Abbott India, a Corporation company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abbott India | Corporation | Mumbai, India | ||||
| Intercosmetica Neuchâtel | Corporation | Neuchatel, Switzerland | ||||
| Lonza Group | Corporation | Basel, Switzerland | ||||
| Vetter Pharma | Private Debt Financed | Ravensburg, Germany | ||||
| Fujifilm Diosynth Biotechnologies | Corporate Backed or Acquired | College Station, TX |
DSM-Firmenich Patents
DSM-Firmenich Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4480319-A1 | Granola cluster | Pending | 22-Jun-2023 | ||
| EP-4480471-A1 | Specific compounds for treating signs of skin aging and/or hair aging | Pending | 19-Jun-2023 | ||
| EP-4474477-A1 | Genetically engineered strains with reduced byproduct formation | Pending | 07-Jun-2023 | ||
| US-20240409972-A1 | Genetically engineered strains with reduced byproduct formation | Pending | 07-Jun-2023 | ||
| EP-4458828-A1 | A continuous process for producing chiral lactones | Pending | 05-May-2023 | C07D491/04 |
DSM-Firmenich Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
DSM-Firmenich Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
DSM-Firmenich Investments & Acquisitions (85)
DSM-Firmenich’s most recent deal was a Later Stage VC with One.bio for . The deal was made on 07-Nov-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| One.bio | 07-Nov-2024 | Later Stage VC | Biotechnology | ||
| Octarine Bio | 08-Nov-2023 | Later Stage VC | Biotechnology | ||
| Adare Biome | 03-Jul-2023 | Merger/Acquisition | Pharmaceuticals | ||
| Tasman (Fonterra Cooperative Group / Koninklijke DSM) | 01-Jan-2023 | Joint Venture | Food Products | ||
| Prodap | 31-Aug-2022 | Merger/Acquisition | Business/Productivity Software |
DSM-Firmenich ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
16.77 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,104
Rank
Percentile
Pharmaceuticals
Industry
of 851
Rank
Percentile
Pharmaceuticals
Subindustry
of 424
Rank
Percentile
DSM-Firmenich Exits (12)
DSM-Firmenich’s most recent exit was on 29-Sep-2020 from Adaptive3D. The exit was categorized as with 7 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Adaptive3D | 29-Sep-2020 | Completed |
|
||
| Japan Fine Coatings Company | 01-Jan-2016 | Completed |
|
||
| NanoHolding | 09-Nov-2015 | Completed |
|
||
| Reverdia (Biotechnology) | 28-Mar-2012 | Completed |
|
||
| Qolpac | 01-Jan-2009 | Merger/Acquisition | Completed |
Affiliates
Subsidiaries (14)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Stichting Pensioenfonds DSM Nederland | Sittard, Netherlands | 2014 | |
| BioCare Copenhagen | Broendby, Denmark | 2012 | |
| Glycom | Horsholm, Denmark | 2005 | |
| Yantai Andre Pectin | Yantai, China | 2003 | |
| dsm-firmenich Venturing | Heerlen, Netherlands | 2001 |
DSM-Firmenich FAQs
-
When was DSM-Firmenich founded?
DSM-Firmenich was founded in 1902.
-
Where is DSM-Firmenich headquartered?
DSM-Firmenich is headquartered in Kaiseraugst, Switzerland.
-
What is the size of DSM-Firmenich?
DSM-Firmenich has 30,000 total employees.
-
What industry is DSM-Firmenich in?
DSM-Firmenich’s primary industry is Pharmaceuticals.
-
Is DSM-Firmenich a private or public company?
DSM-Firmenich is a Public company.
-
What is DSM-Firmenich’s stock symbol?
The ticker symbol for DSM-Firmenich is DSFIR.
-
What is the current stock price of DSM-Firmenich?
As of 22-Jan-2025 the stock price of DSM-Firmenich is $103.18.
-
What is the current market cap of DSM-Firmenich?
The current market capitalization of DSM-Firmenich is $27.4B.
-
Who are DSM-Firmenich’s competitors?
Abbott India, Intercosmetica Neuchâtel, Lonza Group, Vetter Pharma, and Fujifilm Diosynth Biotechnologies are some of the 18 competitors of DSM-Firmenich.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
